Notices. Notice
248 words·~1 min read·
/register/2002/09/20/02-23853·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 3710-08-M DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Method for Detecting Clostridium Botulinum Neurotoxin Serotypes, A, B, E and F in a Sample AGENCY: Department of the Army, DOD. ACTION: Notice. SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 09/952,078 entitled “Method for Detecting Clostridium Botulinum Neurotoxin Serotypes A, B, E and F in a Sample,” filed September 14, 2001.
Foreign rights (PCT/US01/28641) are also available. The United States Government, as represented by the Secretary of the Army has rights in this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney,
(301)619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment,
(301)619-6664, both at telefax
(301)619-5034. SUPPLEMENTARY INFORMATION: Sensitive and specific enzyme-linked immunosorbent assays which detect Clostridium botulinum neurotoxins serotypes A, B, E, and F in a sample are described. The assay is based upon affinity-purified antibodies directed against the C-fragments of each toxin. These assays demonstrate sensitivity close to that of the mouse bioassay without the use of animals and in a much simpler format than other assays of similar sensitivity. Luz D. Ortiz, Army Federal Register Liaison Officer. [FR Doc. 02-23853 Filed 9-19-02; 8:45 am]
Connectionstraces to 1
Traces to 1 document